PT  - JOURNAL ARTICLE
AU  - Veiga Teijeiro, Iria
AU  - Guzmán Peralta, Indhira
AU  - Pérez De Llano, Luis
AU  - Martín Robles, Irene
AU  - Blanco Cid, Nagore
AU  - Dacal Rivas, David
AU  - Davila, Ignacio
AU  - Martínez-Moragón, Eva
AU  - Domínguez Ortega, Javier
AU  - Almonacid, Carlos
AU  - Colás, Carlos
AU  - García-Rivero, Juan Luis
AU  - Carmona, Loreto
AU  - García De Yébenes, María Jesús
AU  - García-Cosío, Borja
TI  - Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score
AID  - 10.1183/13993003.congress-2021.PA1098
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA1098
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA1098.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA1098.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Background: There is a lack of tools to holistically quantify the response to monoclonal antibodies (mAbs) in severe uncontrolled asthma (SUA) patients. The aim of this study was to develop a valid score to assist specialists in this clinical context.Methods: The score was developed in 4 subsequent phases: (1) elaboration of the theoretical model of the construct intended to be measured (response to mAbs); (2) definition and selection of items and measurement instruments by Delphi survey; (3) weight assignment of the selected items by multicriteria decision analysis (MCDA) using the Potentially All Pairwise RanKings of all possible Alternatives (PAPRIKA) methodology via the 1000Minds software; and (4) face validity assessment of the obtained score.Results: Four core items, with different levels of response for each of them, were selected: “severe exacerbations”, “oral corticosteroid use”, “symptoms” (evaluated by Asthma Control Test: ACT) and “bronchial obstruction” (assessed by FEV1% theoretical). “Severe exacerbations” and “oral corticosteroid maintenance dose” were weighted most heavily (38% each), followed by “symptoms” (13%) and “FEV1” (11%). Higher scores in the weighted system indicate better response and the range of responses runs from 0 (worsening) to 100 (best possible response). Face validity was high (intraclass correlation coefficient: 0.86).Conclusions: The FEOS score (FEV1, Exacerbations, Oral corticosteroids, Symptoms) allows clinicians to quantify response in SUA patients who are being treated with mAbs.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA1098.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).